Exact Sciences Corporation $EXAS Shares Sold by Nippon Life Global Investors Americas Inc.

Nippon Life Global Investors Americas Inc. lowered its position in Exact Sciences Corporation (NASDAQ:EXAS) by 12.0% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 87,510 shares of the medical research company’s stock after selling 11,920 shares during the period. Nippon Life Global Investors Americas Inc.’s holdings in Exact Sciences were worth $4,788,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of EXAS. Integrated Wealth Concepts LLC purchased a new position in Exact Sciences during the first quarter worth approximately $604,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Exact Sciences by 11.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,186 shares of the medical research company’s stock worth $921,000 after buying an additional 2,231 shares during the period. Great Lakes Advisors LLC lifted its position in shares of Exact Sciences by 3.7% during the 1st quarter. Great Lakes Advisors LLC now owns 4,971 shares of the medical research company’s stock valued at $215,000 after buying an additional 178 shares in the last quarter. Focus Partners Wealth lifted its position in shares of Exact Sciences by 12.6% during the 1st quarter. Focus Partners Wealth now owns 21,548 shares of the medical research company’s stock valued at $933,000 after buying an additional 2,413 shares in the last quarter. Finally, Parallel Advisors LLC grew its stake in Exact Sciences by 120.1% in the 2nd quarter. Parallel Advisors LLC now owns 799 shares of the medical research company’s stock valued at $42,000 after acquiring an additional 436 shares during the period. 88.82% of the stock is currently owned by institutional investors and hedge funds.

Exact Sciences Stock Performance

Shares of Exact Sciences stock opened at $102.43 on Friday. The firm has a market cap of $19.54 billion, a PE ratio of -19.25, a price-to-earnings-growth ratio of 2.42 and a beta of 1.40. The company has a quick ratio of 2.44, a current ratio of 2.72 and a debt-to-equity ratio of 0.93. Exact Sciences Corporation has a 52 week low of $38.81 and a 52 week high of $102.66. The business’s fifty day simple moving average is $96.52 and its 200-day simple moving average is $68.59.

Exact Sciences (NASDAQ:EXAS) last issued its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.11. The firm had revenue of $850.74 million for the quarter, compared to analyst estimates of $810.42 million. Exact Sciences had a negative net margin of 32.01% and a positive return on equity of 1.67%. Exact Sciences’s revenue was up 20.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.21) EPS. Equities analysts forecast that Exact Sciences Corporation will post -0.58 earnings per share for the current year.

Wall Street Analysts Forecast Growth

EXAS has been the topic of several research analyst reports. Canaccord Genuity Group lowered shares of Exact Sciences from a “buy” rating to a “hold” rating and lifted their target price for the company from $85.00 to $105.00 in a research report on Tuesday, November 25th. TD Cowen cut Exact Sciences from a “strong-buy” rating to a “hold” rating in a report on Monday, November 24th. Zacks Research raised Exact Sciences from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Exact Sciences in a research report on Wednesday, October 8th. Finally, Evercore ISI set a $105.00 price target on Exact Sciences and gave the stock an “in-line” rating in a research report on Monday, January 5th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, twenty have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $87.06.

Insider Activity at Exact Sciences

In related news, EVP Brian Baranick sold 2,858 shares of the stock in a transaction that occurred on Tuesday, November 4th. The shares were sold at an average price of $70.08, for a total transaction of $200,288.64. Following the completion of the transaction, the executive vice president owned 22,368 shares of the company’s stock, valued at approximately $1,567,549.44. This trade represents a 11.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Jacob A. Orville sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 19th. The shares were sold at an average price of $75.00, for a total value of $375,000.00. Following the completion of the sale, the executive vice president directly owned 23,237 shares in the company, valued at approximately $1,742,775. The trade was a 17.71% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 1.20% of the company’s stock.

About Exact Sciences

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.